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Poster Presentations: P1 P173genotype. Statistical analysis was performed on carriers of the rs45455403
genotype, to determine its predictor value for specific cognitive features.
Over 80 neurological characteristics were explored for significant differ-
ences between the wild-type and the rs45455403 polymorphism carriers.
Results: Observed cognitive differences between the wild-type and the
rs45455403 polymorphism carriers included processing speed, naming,
word-finding difficulties, problems with verbal repetition, reading, judg-
ment, following instructions, sense of direction, anxiety, and insight to
memory loss. Thesewere observed even in subjects without overt symptoms
of dementia. An additional 100 specimens from African-American individ-
uals with careful cognitive profiling are currently undergoing genetic anal-
ysis. Conclusions: Studying the cognitive spectrum of patients carrying the
rs45455403 genotype can help identify the earliest manifestations of Alz-
heimer’s disease in this African-American sub-group. Clinical characteriza-
tion of this genetic subgroup may assist the identification of at-risk
individuals or the clinical biomarkers for early diagnosis and/or progression.
Current research suggests that early disease-modifying interventions or pre-
vention strategies are highly effective for at-risk patients.
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Background: FK506 binding protein 51kDa (FKBP51/FKBP5) is a heat
shock protein 90 kDa (Hsp90) co-chaperone known to regulated tau biology.
Tau is a microtubule associated protein that becomes hyperphosphorylated
and forms intracellular neurofibullary tangles in the brain leading to Alz-
heimer’s disease (AD). Neuronal death in AD exceeds the number of tau tan-
gles, which suggests other toxic tau species are involved in
neurodegeneration.Methods: Biochemical analysis of recombinant protein
was performed using circular dichroism (CD), dynamic light scattering
(DLS), and atomic force microscopy (AFM). Stereotaxic injections were
used to deliver FKBP5 tagged AAV particles into the hippocampus of
rTg4510 tau mice. Immunohistochemistry was performed on brain tissue
to evaluate tau protein levels. Human mRNA and DNAwere evaluated for
FKBP5 gene expression and methylation respectively. Results: In vitro re-
combinant tau assays reveal that FKBP51 works in coordination with Hsp90
to preserve tau from proteasomal degradation in an oligomeric state. In vivo,
FKBP5 overexpression preserves neurotoxic, oligomeric tau. In the human
brain, FKBP5 mRNA expression levels dramatically increase while FKBP5
DNA methylation decreases with age. In AD, FKBP5 mRNA expression
levels positively correlate with Braak staging, and inversely correlate with
FKBP5 methylation.Conclusions: FKBP51 is able to prevent tau clearance
by the proteasome, preserving tau in an oligomeric form that is neurotoxic.
FKBP51 is up-regulated with aging and increases further in AD. Overall
these data suggest high FKBP51 expression creates a proteostatic imbalance
leading to tau toxicity. Therefore, FKBP51 may accelerate AD onset and
progression, suggesting that strategies targeting this Hsp90 co-chaperone
could be therapeutically relevant for AD and other tauopathies.
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Background:We are investigating a 3-generation autosomal dominant fam-
ily with a clinical diagnosis compatible with Alzheimer disease (AD) (onset
66.867.4 years (N¼13; age range 47-77 years). In a whole-genome linkage
study, we linked the family to a genomic region of 5.44 Mb at 7q36 (Rade-
makers et al. AJHG, 2005). Exonic sequencing of 29 genes as well as dosage
analysis using array-based comparative genomic hybridization (aCGH)
identified one synonymous mutation in PAXIP1. However, we could not
provide convincing evidence for a functional role of PAXIP1 in disease pa-
thology leaving the possibility that another mutation at this locus might ex-
plain the observed linkage. Therefore, we used next generation sequencing
(NGS) technology to re-examine the linked candidate region at 7q36.
Methods: Four distantly related patients were selected and whole genome
sequencing (WGS) was performed by Complete Genomics, Inc. The
WGS data was analyzed using an in-house developed software tool Ge-
nomeComb. Sequenom MassARRAY  and Sanger sequencing were used
for validation, for segregation in the family and for screening of control in-
dividuals (N¼1029) and AD patients (N¼1263). Results: The sequence of
the linked region was extracted from the WGS data and compared between
the 4 patients. To select truly called, novel or rare variations (MAF <1%),
we applied quality and frequency filters. We identified 93 heterozygous var-
iations that were shared between the 4 patients of which 35 were segregating
within the family including the one in PAXIP1. After testing the 35 segre-
gating variations in the control cohort only 4 variations remained for further
analyses. Interestingly, is that 3 of these 4 variations are located in the same
gene and cluster in the same intron. The remaining one is an intergenic var-
iation. All 4 variations affect sequences of open chromatin and involve pu-
tative transcription factor binding sites (ENCODE project data).
Conclusions: TheWGS approach is a promising tool to identify linked var-
iations in non-coding regions in an unresolved locus identified in an ex-
tended AD family. The clustering of the variations is indicative for
a putative pathogenic role by influencing the expression and/or regulation
of nearby genes.
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Background: Alzheimer’s disease (AD) is a multigenetic disorder. A large
number of risk variants have been discovered influencing the risk of spo-
radic AD, among which APOE is the strongest risk factor. Several studies
found a significant association between single nucleotide polymorphisms
(SNPs) in the sortilin-related receptor (SORL1) gene on chromosome 11
and AD. SORL1 plays an important role in the intracellular trafficking of
APP and is also a low-density lipoprotein receptor. We evaluated how
SORL1 SNPs influence manifestation of disease in terms of cognitive pro-
file, hippocampal atrophy and cerebrospinal fluid (CSF) biomarkers in AD
patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Methods: 83 caucasian patients (non-hispanic and non-latino) with proba-
ble AD were included from the ADNI. We selected 8 SNPs from the geno-
typed data coming from the ADNI database and imputed 11 SNPs. All SNPs
were dichotomized based on presence of at least one risk allele. As depen-
dent variables we used measures of cognitive performance (Mini Mental
State Exame (MMSE) and Alzheimer’s Disease Assessment Scale
(ADAS)), hippocampal volumes and the CSF biomarkers Amyloid-beta1-
42 (abeta), total tau and tau phosporylated at threonine 181 (ptau). First
we used univariate linear regression to assess associations between SNPs
